Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
Provided By GlobeNewswire
Last update: Oct 22, 2024
Dose-dependent efficacy observed with favorable safety profile
Attractive tumor to kidney ratios shown in biodistribution studies
Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation therapy
Read more at globenewswire.comNASDAQ:MOLN (2/21/2025, 8:00:01 PM)
4.681
-0.23 (-4.75%)
Find more stocks in the Stock Screener
